Board of Directors (2022-2025)
William Pao, MD, PhD, is chief executive officer of Revelio Therapeutics, Inc. Prior to joining Revelio Therapeutics, Dr. Pao led the Global Product Development organization, which is responsible for the clinical development and advancement of Pfizer’s pipeline of innovative medicines, as well as regulatory affairs in support of Pfizer’s R&D pipeline and portfolio of marketed therapies. He has also served as a member of Pfizer’s Executive Leadership Team, the head of Roche Pharma Research and Early Development, and a member of Roche’s Enlarged Corporate Executive Committee. Before joining Roche, he held key positions at Vanderbilt University and at Vanderbilt-Ingram Cancer Center. Dr. Pao received his undergraduate degree from Harvard, and his MD and PhD degrees from Yale University. Following his residency training in Internal medicine at New York-Presbyterian Hospital/Weill-Cornell Medical School Campus, he completed his medical oncology and postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center.
AACR Board of Directors